Reuters (6/1) reported that, according to a
study published online in BMJ, the diabetes medication Actos (pioglitazone) may
be linked to an increased risk of bladder cancer.
HealthDay (6/1, Reinberg) reported that
investigators "collected data on nearly 116,000 people treated for
diabetes from 1988 to 2009 and listed in the General Practice Research
Database, which contains records from more than 600 medical offices in the
United Kingdom."
MedPage Today (6/1, Walsh) added that
"patients with type 2 diabetes who were ever treated with pioglitazone had
an 83% higher risk for bladder cancer (adjusted rate ratio 1.83, 95% CI 1.10 to
3.05) than those who had never used the thiazolidinedione." The
investigators reported that "this was a drug-specific effect, because
patients taking rosiglitazone (Avandia) did not have an elevated risk (RR 1.14,
95% CI 0.78 to 1.68)." The findings from "this analysis differed from
those of a study being presented this week at the annual meeting of the
American Society of Clinical Oncology, which suggested that the bladder cancer
risk was a class effect for glitazones." Also covering the story was the
UK's Telegraph
No comments:
Post a Comment